Detalles de la búsqueda
1.
Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.
Hum Vaccin Immunother
; 17(7): 2107-2116, 2021 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33626291
2.
Immune Response Persistence and Safety of a Booster Dose of the Tetravalent Dengue Vaccine in Adolescents and Adults Who Previously Completed the 3-dose Schedule 4-5 Years Earlier in Latin America: A Randomized Placebo-controlled Trial.
Pediatr Infect Dis J
; 39(10): 961-968, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32932330
3.
Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
PLoS Negl Trop Dis
; 10(7): e0004830, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27459266
Resultados
1 -
3
de 3
1
Próxima >
>>